Hypopharyngeal dedifferentiated liposarcoma: What we have learned so far

Touli, Ermioni; Manganaris, Argyrios; Katsiki, Evangelia; Karasmanis, Ilias

doi:10.1016/j.oraloncology.2021.105599

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chemotherapy plays a limited role in treating symptomatic recurrence and metastatic disease. Trabectedin and eribulin for metastatic liposarcoma and CDK4 INHIBITORs for CDK4 amplified liposarcoma have been proposed as targeted therapies for such patients 6 9 10…”

Section: Discussionmentioning

confidence: 99%

Hazardous giant pharyngoesophageal liposarcoma

et al. 2022

View full text Add to dashboard Cite

A man in his early 80s presented to the otorhinolaryngology department with progressively worsening dysphagia to solids and a recent episode of difficulty breathing accompanied by a very brief expulsion of a solid mass from the mouth. Based on the endoscopic appearance of a fatty lesion of an elongated mass with a thick stalk on the posterior pharyngeal wall, a diagnosis of the benign fibrovascular polyp was given after clinical and radiological correlation. The pharyngeal polyp was resected at the base of its pedicle by transoral endoscopy with a thunder beat vessel sealing device. Histopathological examination of the mass revealed a well-differentiated liposarcoma composed of mature adipocytes. Following surgical excision, the patient made a full recovery. This case signifies the integrated role of preoperative biopsy, new surgical technologies and targeted therapies in managing pharyngoesophageal polyps.

show abstract

Section: Discussionmentioning

confidence: 99%